The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1485628
This article is part of the Research Topic Unveiling Biomarkers and Mechanisms in the Tumor-Immune Nexus View all 25 articles
Extracellular Vesicles in Hepatocellular Carcinoma: Unraveling Immunological Mechanisms for Enhanced Diagnosis and Overcoming Drug Resistance
Provisionally accepted
Lanqian Su
1
Yuxin Yue
2
Yan YaLan
1
Jianmin Sun
3*
Lanxin Meng
1*
Jiaan Lu
1
Lanyue Zhang
1*
Jie Liu
3
Hao Chi
1
Sinian Liu
4*
Zhongqiu Yang
3*
Xiaowei Tang
5*- 1 School of Clinical Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China
- 2 Department of Pediatrics, Southwest Medical University, Luzhou, Sichuan Province, China
- 3 Department of General Surgery, Dazhou Central Hospital, DaZhou, China
- 4 Department of Pathology, Xichong People’s Hospital, Nanchong, China
- 5 Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
Current research is focused on utilizing EVs as a biopsy tool to improve the diagnostic accuracy of HCC, reduce surgical risk, and explore their potential in modulating drug resistance and advancing immunotherapeutic strategies. Extracellular vesicles (EVs) have been increasingly recognized as important non-invasive biomarkers in hepatocellular carcinoma (HCC) due to the presence of a variety of biomolecules within them, such as proteins and RNAs, etc. EVs play a key role in the early detection, diagnosis, treatment, and prognostic monitoring of HCC. These vesicles influence the development of HCC and therapeutic response in a variety of ways, including influencing the tumor microenvironment, modulating drug resistance, and participating in immune regulatory mechanisms. In addition, specific molecules such as miRNAs and specific proteins in EVs are regarded as potential markers for monitoring treatment response and recurrence of HCC, which have certain research space and development prospects. In this paper, we summarize the aspects of EVs as HCC diagnostic and drug resistance markers, and also discuss the questions that may be faced in the development of EVs as markers.
Keywords: extracellular vesicles, Hepatocellular Carcinoma, Tumor marker, diagnosis, Drug Resistance
Received: 24 Aug 2024; Accepted: 08 Oct 2024.
Copyright: © 2024 Su, Yue, YaLan, Sun, Meng, Lu, Zhang, Liu, Chi, Liu, Yang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jianmin Sun, Department of General Surgery, Dazhou Central Hospital, DaZhou, China
Lanxin Meng, School of Clinical Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China
Lanyue Zhang, School of Clinical Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan Province, China
Sinian Liu, Department of Pathology, Xichong People’s Hospital, Nanchong, China
Zhongqiu Yang, Department of General Surgery, Dazhou Central Hospital, DaZhou, China
Xiaowei Tang, Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.